New seizure drug shows promise in major trial

NCT ID NCT07505004

Recruiting now Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study tests a new medicine called vormatrigine for adults with focal seizures (a type of epilepsy). About 300 people who already take 1 to 3 seizure drugs will receive either vormatrigine or a placebo. The goal is to see if vormatrigine reduces seizure frequency more than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Praxis Research Site
RECRUITING

Miami, Florida, 33133, United States
Praxis Research Site
RECRUITING

Miami Lakes, Florida, 33016, United States
Praxis Research Site
NOT_YET_RECRUITING

Naples, Florida, 34116, United States
Praxis Research Site
RECRUITING

Marlboro, New Jersey, 07746, United States
Praxis Research Site
RECRUITING

Niagara Falls, New York, 14304, United States
Praxis Research Site
RECRUITING

Raleigh, North Carolina, 27607, United States
Praxis Research Site
RECRUITING

Houston, Texas, 77058, United States

Conditions

Explore the condition pages connected to this study.

FOCAL EPILEPSY